ALEFACEPT (a la FA cept) is used to treat adult patients with moderate or severe chronic plaque psoriasis.
Alefacept is a genetically engineered immunosuppressive drug. It was sold under
the brand name Amevive in Canada, the United States, Israel, Switzerland and ...
AMEVIVE® (alefacept) is a CD2-directed LFA-3/Fc fusion protein that consists of
the extracellular CD2-binding portion of the human leukocyte function antigen-3 ...
Jun 11, 2015 ... Alefacept (Amevive) medication for adults with moderate to severe placuqe
psoriasis. Side effects, dosage, pregnancy safety information, and ...
Nov 16, 2011 ... Astellas Pharma U.S. Inc. (Astellas) has voluntarily discontinued the promotion,
manufacturing, distribution and sales of Amevive (alefacept), ...
Alefacept is the first biological agent approved by the US Food and Drug
Administration (FDA) for the treatment of moderate to severe chronic plaque
Amevive (alefacept): For moderate to severe chronic plaque psoriasis.. New
approved drug details including side effects, uses and general information.
Easy to read patient leaflet for alefacept. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Amevive (alefacept) is a protein that reduces specific actions of the immune
system that are involved in causing psoriasis. Amevive is used to treat plaque ...
(alefacept) is an immunosuppressive dimeric fusion protein that consists of ...
intravenous injection contains 7.5 mg alefacept per 0.5 mL of reconstituted